Table S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Flaminia Pedretti, Violeta Serra(Vall d'Hebron Institute of Oncology), Laia Monserrat(Vall d'Hebron Institut de Recerca), Herena Eixarch(Universitat Autònoma de Barcelona), Judit Grueso(University of North Carolina at Chapel Hill), Juan C. Nieto(Centre for Genomic Regulation), Roberta Fasani(Vall d'Hebron Institute of Oncology), Olga Rodríguez(University of North Carolina at Chapel Hill), Paula Martínez-Sanz(Sanquin), Mark J. O’Connor(AstraZeneca (United Kingdom)), Lara Nonell(Universitat Autònoma de Barcelona), S. Simonetti(Nova Southeastern University), Andreu Òdena(Vall d'Hebron Institute of Oncology), Dražen Papić(Humboldt-Universität zu Berlin), Joan Seoane(Institució Catalana de Recerca i Estudis Avançats), Alba Llop‐Guevara(Vall d'Hebron Institut de Recerca), Francesca Mateo(Institut d'Investigació Biomédica de Bellvitge), Stefan Florian(German Cancer Research Center), Holger Heyn(Scope Group (United States)), Anna Pascual Reguant(German Rheumatism Research Centre), Carmen Espejo(Universitat Autònoma de Barcelona), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Andrea Herencia-Ropero(Marine Hydrophysical Institute), Judith Balmañà(Vall d'Hebron Hospital Universitari), Viia Valge-Archer(AstraZeneca (United Kingdom)), Marta Guzmán(University of North Carolina at Chapel Hill), Alba Mas Malavila(Vall d'Hebron Institut de Recerca), Heura Domènech(Vall d'Hebron Institut de Recerca), Mohmed Abdalfttah(Centro Nacional de Análisis Genómico), Benedetta Pellegrino(University of Parma), Pau Clavell-Revelles(Vall d'Hebron Institut de Recerca), Miguel Ángel Pujana(Bellvitge University Hospital)
Cited by 0
Related Papers
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
|Immunity|2016|1.1k
Network modeling links breast cancer susceptibility and centrosome dysfunction
|Nature Genetics|2007|634